BioSpace News Archive

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 24, 2018 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.

On Tuesday, key US indices were mixed as the NASDAQ Composite finished the trading session down 0.01%; the Dow Jones Industrial Average edged 0.79% higher; and the S&P 500 was up 0.48%.

Clearance allowing the test to be sold as an in vitro diagnostic for the diagnosis of tuberculosis in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval.

The company is best known for its industry-leading nutritional supplement brands Nugenix®, Instaflex®, Peptiva®, and Lumiday®

Boston Scientific Corporation generated sales of $2.490 billion during the second quarter ended June 30, 2018.

KEYTRUDA is the First Anti-PD-1 Therapy to Show an Overall Survival Benefit as First-Line Therapy for Recurrent or Metastatic HNSCC

Indivior Announces H1 2018 Results

Successful progression of clinical projects

EBD Group has released a significant update of its gold-standard partnering software, partneringONE®, based on a fully responsive mobile platform.

Led Stakeholder Engagement for the FDA’s Center for Drug Evaluation and Research